Search details
1.
Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).
Breast Cancer Res Treat
; 205(2): 211-226, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38355821
2.
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERß and Mutant p53.
Oncologist
; 28(4): 358-363, 2023 04 06.
Article
in English
| MEDLINE | ID: mdl-36772966
3.
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study).
Breast Cancer Res Treat
; 199(3): 501-509, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37103597
4.
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.
Oncologist
; 27(11): 930-939, 2022 11 03.
Article
in English
| MEDLINE | ID: mdl-35852437
5.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Article
in English
| MEDLINE | ID: mdl-30786188
6.
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast).
Breast Cancer Res Treat
; 193(3): 579-587, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35441995
7.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34860318
8.
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
J Natl Compr Canc Netw
; 20(6): 723-734, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714678
9.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714673
10.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34264439
11.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
; 189(2): 411-423, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34302589
12.
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Breast Cancer Res Treat
; 189(3): 641-651, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34417675
13.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34120223
14.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
J Natl Compr Canc Netw
; : 1-8, 2021 Mar 24.
Article
in English
| MEDLINE | ID: mdl-33761455
15.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
J Natl Compr Canc Netw
; 19(5): 484-493, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-34794122
16.
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Nature
; 518(7538): 240-4, 2015 Feb 12.
Article
in English
| MEDLINE | ID: mdl-25409150
17.
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
J Oncol Pharm Pract
; 27(8): 1883-1890, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-33153384
18.
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
Oncologist
; 25(8): 652-660, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32463152
19.
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
Breast Cancer Res Treat
; 183(3): 515-524, 2020 Oct.
Article
in English
| MEDLINE | ID: mdl-32712878
20.
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
Breast Cancer Res Treat
; 181(3): 487-497, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32333293